Emulated Trial Puts Surgery Ahead of SABR in Early-Stage NSCLC

Stereotactic ablative radiotherapy SABR has long held an important place in the treatment of early-stage non-small cell lung cancer for patients who cannot safely undergo surgery. The harder question has been whether it can stand beside surgical resection as a true alternative in patients fit for either approach. A new emulated target trial using England’s national cancer registry data gives that comparison real-world shape, and the mortality signal leans toward surgery.

The study drew on patients diagnosed with T1-2N0M0 disease between 2015 and 2020, limited to those age 18 to 79 years with Zubrod performance status 0-2, or age 80 years and older with performance status 0-1, who received either SABR or surgical resection within 6 months of diagnosis. Treatment exposure was established through linkage with Hospital Episode Statistics and the National Radiotherapy Data Set, a design meant to capture treatment delivery with greater fidelity than routine registry coding alone. The investigators also used instrumental variable analysis to reduce confounding by indication, a critical step in a comparison where frailer patients are naturally more likely to receive radiotherapy rather than an operation.

The cohort was large enough to give the analysis weight: 12,546 individuals met eligibility criteria, including 2,299 treated with SABR and 10,247 treated with surgery.

Mortality Separation Favored Surgical Resection

Three-year all-cause mortality was 30.3% after SABR and 21.6% after surgery. After adjustment, the mean absolute risk difference was 8.8 percentage points, with a 95% confidence interval of 1.4 to 16.2, and the difference reached statistical significance with a P value of .02. In practical terms, the survival curves did not simply drift apart; they separated in a way that suggests a real outcome penalty for SABR in this mixed but treatment-eligible population.

The biology behind that gap is plausible. Surgical resection removes the primary tumor outright and provides pathologic staging, which can uncover occult nodal disease or high-risk features that imaging misses. SABR can eradicate a localized lesion with impressive conformality, but it does not supply tissue for staging, margin assessment, or the downstream information that often guides adjuvant planning. In early-stage lung cancer, those missing pieces can matter when microscopic spread is present but invisible on imaging.

A separate lung cancer-specific mortality analysis pointed in the same direction, though with less statistical certainty. Estimated 3-year lung cancer-specific mortality was 20.6% after SABR and 14.5% after surgery, with an adjusted mean absolute risk difference of 6.1 percentage points and a 95% confidence interval ranging from -0.6 to 12.9. The P value of .07 stopped short of conventional significance. Even so, the direction of effect mirrors the all-cause mortality finding and leaves little comfort for the idea that SABR is equivalent to surgery in patients who can reasonably receive either treatment.

Recurrence was included as a secondary outcome, but the abstract does not provide the recurrence estimates. Even without that detail, the mortality findings alone are enough to shift the clinical conversation. Survival remains the endpoint that matters most when the treatment choice is meant to be curative.

Older Patients Showed a Smaller Gap

The age-stratified analysis is where the findings become more nuanced without reversing the overall conclusion. Among patients age 80 years and older, the adjusted mean absolute risk difference in 3-year all-cause mortality was 4.3 percentage points, with a 95% confidence interval of -3.7 to 12.3 and a P value of .62. In this older subgroup, the mortality difference was not statistically significant.

That pattern fits bedside reality. Older adults carry a heavier burden of competing risks, and non-cancer mortality can dilute the measurable advantage of the more invasive approach. Surgical resection may still offer the strongest cancer control, but in an octogenarian with limited physiologic reserve, the balance between oncologic benefit and procedural burden becomes narrower. SABR remains a curative-intent option in that setting, especially when perioperative risk, frailty, or patient preference makes surgery less attractive.

Still, the subgroup result should not be read as proof of equivalence. The confidence interval crosses both modest benefit and harm, which means the estimate is imprecise rather than reassuring. For older patients who are otherwise fit enough to consider surgery, the study does not erase the survival advantage seen in the overall cohort.

Why This Emulated Trial Matters for Practice

Randomized trials have struggled to answer this question directly because recruitment has failed and ongoing studies often use restrictive eligibility criteria. The result is a persistent evidence gap in a population where the choice between SABR and surgery is made every day. This emulated target trial does not replace randomization, but it does offer something clinically valuable: a large, contemporary comparison of treatment strategies in patients who were eligible for either modality.

The study’s design also reflects the reality of modern oncology research. When randomization is not feasible, high-quality observational methods can still inform practice if treatment assignment is carefully modeled and sources of bias are addressed head-on. Instrumental variable analysis cannot eliminate every concern about residual confounding, yet it strengthens the inference that the mortality difference is not just a reflection of frailer patients being preferentially steered toward SABR.

The conclusion is direct. In early-stage NSCLC suitable for either treatment, surgical resection should remain the preferred option. SABR continues to serve an essential curative role for patients who are not surgical candidates, and it may be particularly useful in older people whose competing health risks blunt the relative advantage of an operation. But for patients who can safely undergo resection, the survival data here favor surgery, and the magnitude of the difference is large enough to shape counseling at the time of treatment selection.

The study leaves one key clinical tension unresolved: how best to identify the subgroup of older, fit patients who might still derive outcomes close to surgery with SABR. Until better comparative evidence emerges, the burden of proof remains on SABR if it is to displace surgery in patients who can tolerate an operation.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by Journal of Clinical Oncology (JCO).
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA